• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

熔融分散颗粒:改善难溶性药物口服给药的制剂与评价——以缬沙坦为例

Melt dispersion granules: formulation and evaluation to improve oral delivery of poorly soluble drugs - a case study with valsartan.

作者信息

Chella Naveen, Tadikonda Ramarao

机构信息

National Institute of Pharmaceutical Education and Research , Hyderabad, Andhra Pradesh , India .

出版信息

Drug Dev Ind Pharm. 2015 Jun;41(6):888-97. doi: 10.3109/03639045.2014.911308. Epub 2014 May 5.

DOI:10.3109/03639045.2014.911308
PMID:24796274
Abstract

Solid dispersion (SD) technique is a promising strategy to improve the solubility and dissolution of BCS class II drugs. However, only few products are marketed till today based on SD technology due to poor flow properties and stability. The present work was intended to solve these problems by using combination approach, melt dispersion and surface adsorption technologies. The main aim of the present work is to improve the absorption in the stomach (at lower pH) where the absorption window exists for the drug by improving the dissolution, resulting in the enhancement of oral bioavailability of poorly soluble, weakly acidic drug with pH dependant solubility, i.e. valsartan. Melt dispersion granules were prepared in different ratios using different carriers (Gelucire 50/13, PEG 8000 and Pluronic F-68) and lactose as an adsorbent. Similarly, physical mixtures were also prepared at corresponding ratios. The prepared dispersion granules and physical mixtures were characterized by FTIR, DSC and in vitro dissolution studies. DSC studies revealed reduction in the crystallinity with a possibility of presence of amorphous character of drug in the dispersion granules. From dissolution studies, valsartan Gelucire dispersion (GSD4; 1:4 ratio) showed complete drug release in 30 min against the plain drug which showed only 11.31% of drug release in 30 min. Pharmacokinetic studies of optimized formulation in male Wistar rats showed 2.65-fold higher bioavailability and 1.47-fold higher Cmax compared to pure drug. The melt dispersion technology has the potential to improve dissolution and the bioavailability of BCS class II drugs.

摘要

固体分散体(SD)技术是改善BCS II类药物溶解度和溶出度的一种很有前景的策略。然而,由于流动性差和稳定性问题,到目前为止基于SD技术上市的产品很少。本研究旨在通过采用熔融分散和表面吸附技术相结合的方法来解决这些问题。本研究的主要目的是通过改善溶出度来提高药物在胃中(较低pH值)的吸收,胃中存在药物的吸收窗,从而提高具有pH依赖性溶解度的难溶性弱酸性药物(即缬沙坦)的口服生物利用度。使用不同的载体(Gelucire 50/13、PEG 8000和普朗尼克F-68)和乳糖作为吸附剂,以不同比例制备熔融分散颗粒。同样,也以相应比例制备物理混合物。通过傅里叶变换红外光谱(FTIR)、差示扫描量热法(DSC)和体外溶出度研究对制备的分散颗粒和物理混合物进行表征。DSC研究表明结晶度降低,分散颗粒中可能存在药物的无定形特征。从溶出度研究来看,缬沙坦Gelucire分散体(GSD4;1:4比例)在30分钟内显示药物完全释放,而普通药物在30分钟内仅释放11.31%。雄性Wistar大鼠体内优化制剂的药代动力学研究表明,与纯药物相比,生物利用度提高了2.65倍,Cmax提高了1.47倍。熔融分散技术有潜力改善BCS II类药物的溶出度和生物利用度。

相似文献

1
Melt dispersion granules: formulation and evaluation to improve oral delivery of poorly soluble drugs - a case study with valsartan.熔融分散颗粒:改善难溶性药物口服给药的制剂与评价——以缬沙坦为例
Drug Dev Ind Pharm. 2015 Jun;41(6):888-97. doi: 10.3109/03639045.2014.911308. Epub 2014 May 5.
2
Soluplus®/TPGS-based solid dispersions prepared by hot-melt extrusion equipped with twin-screw systems for enhancing oral bioavailability of valsartan.采用配备双螺杆系统的热熔挤出法制备的基于Soluplus®/TPGS的固体分散体,用于提高缬沙坦的口服生物利用度。
Drug Des Devel Ther. 2015 May 22;9:2745-56. doi: 10.2147/DDDT.S84070. eCollection 2015.
3
Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan.含有缬沙坦的聚合物分散体的制剂与药代动力学评价
Eur J Drug Metab Pharmacokinet. 2016 Oct;41(5):517-26. doi: 10.1007/s13318-015-0290-5.
4
Enhanced dissolution and oral bioavailability of valsartan solid dispersions prepared by a freeze-drying technique using hydrophilic polymers.采用冷冻干燥技术,使用亲水性聚合物制备的缬沙坦固体分散体的溶出度和口服生物利用度提高。
Drug Deliv. 2016;23(1):41-8. doi: 10.3109/10717544.2014.903012. Epub 2015 Sep 4.
5
Design of a novel type IV lipid-based delivery system for improved delivery of drugs with low partition coefficient.一种新型IV型脂质递送系统的设计,用于改善低分配系数药物的递送
J Liposome Res. 2015;25(4):325-33. doi: 10.3109/08982104.2015.1010544. Epub 2015 Sep 10.
6
Fabrication and evaluation of pH-modulated solid dispersion for telmisartan by spray-drying technique.喷雾干燥技术制备和评价替米沙坦 pH 调节固体分散体。
Int J Pharm. 2013 Jan 30;441(1-2):424-32. doi: 10.1016/j.ijpharm.2012.11.012. Epub 2012 Nov 19.
7
Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes.新型缬沙坦固体分散体,生物利用度提高,无晶体变化。
Int J Pharm. 2012 Jan 17;422(1-2):202-10. doi: 10.1016/j.ijpharm.2011.10.053. Epub 2011 Nov 6.
8
Design, optimization, preparation and evaluation of dispersion granules of valsartan and formulation into tablets.缬沙坦分散片剂的设计、优化、制备及评价与片剂剂型研究
Curr Drug Deliv. 2009 Jan;6(1):28-37. doi: 10.2174/156720109787048258.
9
Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): Evaluating amorphous state and in vivo performance.固定剂量形式的热熔共配制抗疟固体分散体系统(ARLUMELT)的研发:评估非晶态及体内性能。
Int J Pharm. 2015 Dec 30;496(1):137-56. doi: 10.1016/j.ijpharm.2015.09.069. Epub 2015 Oct 22.
10
Development and optimization of press coated tablets of release engineered valsartan for pulsatile delivery.用于脉冲释放的缓释缬沙坦压制包衣片的研发与优化
Drug Dev Ind Pharm. 2015;41(11):1835-46. doi: 10.3109/03639045.2015.1014374. Epub 2015 Feb 27.

引用本文的文献

1
Ternary Solid Dispersions as an Alternative Approach to Enhance Pharmacological Activity.三元固体分散体作为增强药理活性的替代方法。
Drug Des Devel Ther. 2025 Jul 3;19:5663-5684. doi: 10.2147/DDDT.S533359. eCollection 2025.
2
Spray Congealing: An Emerging Technology to Prepare Solid Dispersions with Enhanced Oral Bioavailability of Poorly Water Soluble Drugs.喷雾凝结:一种新兴技术,可制备固体分散体,提高难溶性药物的口服生物利用度。
Molecules. 2019 Sep 25;24(19):3471. doi: 10.3390/molecules24193471.
3
Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan.
含有缬沙坦的聚合物分散体的制剂与药代动力学评价
Eur J Drug Metab Pharmacokinet. 2016 Oct;41(5):517-26. doi: 10.1007/s13318-015-0290-5.